Clinical Trials Arena on MSN1d
Entrada gains UK MHRA authorisation to start Phase I/II trial of DMD treatment
Entrada Therapeutics has secured authorisation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and ...
Entrada receives authorization in the UK to initiate ELEVATE-45-201 study
Entrada Therapeutics (TRDA) has received authorization from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency and ...
BioWorld3d
Entrada’s ENTR-601-45 gains clearance in UK to enter clinic for Duchenne muscular dystrophy
Entrada Therapeutics Inc. has received authorization from the U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) and research ethics committee to initiate a phase I/II study of ENTR-601 ...
Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year
Wave Life plans a 2026 NDA filing for WVE-N531 after positive Phase 2 data in Duchenne muscular dystrophy, showing functional gains and biomarker improvements.
Mena FN22d
Key Driver In The Amondys 45 Market 2025: Rising Prevalence Of Duchenne Muscular Dystrophy Fuels Growth
The increasing prevalence of DMD is a major factor driving the demand for Amondys 45, a therapy specifically designed for patients with exon 45 mutations. This rise in cases is closely associated ...